



2007 1st half-year sales up 17%
Q2 sales up 13%

(€ millions)	2007		2006		07/06
		% sales		% sales	% change
Southern Europe (1)	23.22	72.0	20.53	71.8	13
Other EU countries (2)	7.69	23.8	6.91	24.2	11
Other markets	1.34	4.2	1.17	4.0	15
SLIT	25.11	77.9	21.76	76.1	15
SCIT	5.65	17.5	5.36	18.7	5
Other products	1.49	4.6	1.49	5.2	-
Total Q2 sales	32.25	100.0	28.61	100.00	13
Southern Europe (1)	56.53	75.6	48.10	74.9	18
Other EU countries (2)	15.76	21.1	13.71	21.4	15
Other markets	2.51	3.3	2.39	3.7	5
SLIT	59.75	79.9	49.42	77.0	21
SCIT	11.82	15.8	11.63	18.1	2
Other products	3.23	4.3	3.15	4.9	3
Total HY1 sales	74.80	100.0	64.20	100.00	17

1. Portugal, Spain, France, Italy, Greece
2. Including Switzerland

2007 **second quarter** sales registered further strong growth in all markets (+13%, vs +11% in 2006).

The most buoyant segment of the market remained desensitisation via the **sublingual route** (SLIT, +15%), whose reputation was enhanced by the launch of allergen tablets. Germany posted the strongest growth of the segment over the quarter (+28% increase in initial treatments, vs +9% in all markets).

Cumulated sales for the **1st half-year** increased by +17% (vs +14% in 2006). This good performance enables the Group to firmly confirm its double-digit growth guidance for 2007.

The marketing authorisation process for ORALAIR® Grasses in Germany is ongoing. The registration file is currently under examination by the German agency Paul Ehrlich Institute.

The launch of ORALAIR® Grasses in Germany is being actively prepared by Stallergènes' sales force for the end of the year. This launch will progressively be extended to other European countries as the mutual recognition procedure successfully progresses throughout Europe.

About STALLERGENES

Stallergènes is a European biopharmaceutical laboratory specialising in the treatment by desensitisation of allergy-related respiratory conditions, such as rhino-conjunctivitis or allergic asthma.

A pioneer and a leader in sublingual desensitisation treatments, Stallergènes devotes 15% of its sales to its Research and Development activities, notably to the development of a new therapeutic range enabling the provision of desensitisation treatments by sublingual tablets.

With its head office in France, Stallergènes markets its products in close to 40 countries. Stallergènes achieved 2006 sales of € 126.5 million, half of which outside France.

Stallergènes' shares are listed on Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP



STALLERGENES

Albert SAPORTA - Chairman
Christian THIRY – Chief Financial Officer
Tél : +33 (0)1 55 59 20 95
investorrelations@stallergenes.fr

PAVIE FINANCE

Lucile de FRAGUIER
Investor & Analyst Relations
Tel: + 33 (0)1 42 15 04 39
contact@pavie-finance.com